NeXstar Forms Technology Products Division

NeXstar Pharmaceuticals Inc. (Boulder, Colo.) has launched a new commercial business unit to market specialty chemicals and process technologies to enhance the research and development of biomacromolecules.

Through the company's proprietary drug discovery and manufacturing technologies, NeXstar has designed and developed multiple proprietary compounds and process technologies related to oligonucleotide drug development and manufacturing.

In addition to serving the company's own development needs, these compounds and technologies may also benefit companies that are interested in the design and development of all biomacromolecules, such as oligonucleotides, proteins and carbohydrates.

"Our process development team has discovered and applied for patents on unique technologies for use in the oligonucleotide industry," said Wolfgang Pieken, Ph.D., NeXstar Pharmaceuticals director of process chemistry.

"With a newly renovated facility encompassing ten thousand square feet of space, we now have the capacity to support commercial projects, and ongoing research enterprises and to gear up for large-scale production requests."

NeXstar plans to launch several research and bulk-scale products from the new technologies business unit during the first half of 1998 to increase efficiency and provide depth to the overall oligonucleotide drug discovery and development program.

NeXstar Pharmaceuticals Inc. is a commercial pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat serious and life-threatening illnesses.